Kenneth D. Burman, MD

Kenneth D. Burman is the Chief of Endocrinology at Medstar Washington Hospital Center (MWHC) and the Director of the Integrated Endocrine Training Program at Medstar Georgetown University/MWHC. 

Dr. Burman received his medical degree from University of Missouri-Columbia followed by internship and residency program from Barnes Jewish Hospital and fellowship from Walter Reed National Military Medical Center.

Kenneth D. Burman has decades of experience in researching and treating the full range of pituitary disorders. He specializes in pituitary endocrinology with expertise in treating thyroid cancer and other thyroid conditions. Dr. Burman leads the endocrinology team at the MedStar Pituitary Center. He conducts some of the latest pituitary disease research, investigating better ways to treat pituitary tumors. 

Dr. Burman’s research is essential to advancing the future of treatments for pituitary disorders. He has published studies investigating the metabolism of thyroid hormone in various clinical states, the role of intrathyroidal lymphocytes in autoimmune thyroid disease, the mechanism of action and the utility of lithium and cholestyramine in the treatment of Graves’ hyperthyroidism. 

Representative Publications:

Improved Survival After Multimodal Approach With 131I Treatment in Patients With Bone Metastasis Secondary to Differentiated Thyroid Cancer

The Effect of Lithium on the Progression-Free and Overall Survival in Patients With Metastatic Differentiated Thyroid Cancer Undergoing Radioactive Iodine Therapy

Synchronous Independent Papillary Thyroid Carcinomas in Struma Ovarii and the Thyroid Gland With Different RAS Mutations

Detection at Public Facilities of 131I In Patients Treated for Differentiated Thyroid Cancer: Frequency, Sites, Management by Security Agents, and Physician Documentation Recommended for Patients

Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer